[
Abe M, Hamano T, Hoshino J, Wada A, Nakai S, Masakane I. Rate of the “burnt-out diabetes” phenomenon in patients on peritoneal dialysis. Diabetes Res Clin Pract 143, 254–262, 2018.10.1016/j.diabres.2018.07.026
]Search in Google Scholar
[
Abe M, Hamano T, Hoshino J, Wada A, Nakai S, Masakane I. Glycemic control and survival in peritoneal dialysis patients with diabetes: A 2-year nationwide cohort study. Sci Rep 9, 3320, 2019.10.1038/s41598-019-39933-5
]Search in Google Scholar
[
American Diabetes Association. 1. Improving Care and Promoting Health in Populations: Standards of Medical Care in Diabetes-2018. Diabetes Care 41, S7–S12, 2018.10.2337/dc18-S001
]Search in Google Scholar
[
Aramwit P, Satirapoj B. Chapter 8. Glycemic control in diabetic patients on long-term maintenance dialysis. In Hemodialysis (Ed. Hiromichi Suzuki), InTechOpen Limited, London, United Kingdom, pp.153–191, 2013.10.5772/52479
]Search in Google Scholar
[
Buell C, Kermah D, Davidson MB. Utility of A1C for diabetes screening in the 1999-2004 NHANES population. Diabetes Care 30, 2233–2235, 2007.10.2337/dc07-0585
]Search in Google Scholar
[
Campbell AK. Detection and quantification of chemiluminescence. In Chemiluminescence principles and applications in biology and medicine (Ed. Ellis Horwood), Chichester, pp. 68–126, 1988.
]Search in Google Scholar
[
Cefalu WT, Buse JB, Tuomilehto J, Fleming GA, Ferrannini E, Gerstein HC, Bennett PH, Ramachandran A, Raz I, Rosenstock J, Kahn SE. Response to Comment on Cefalu et al. Update and next steps for real-world translation of interventions for type 2 diabetes prevention: Reflections from a diabetes care Editors’ Expert Forum. Diabetes Care 39, 1186–1201, 2016. Diabetes Care 40, e23–e24, 2017.10.2337/dci16-0036
]Search in Google Scholar
[
Chen CW, Drechsler C, Suntharalingam P, Karumanchi A Christoph Wanner C, Berg AH. High glycated albumin and mortality in persons with diabetes mellitus on hemodialysis. Clin Chem 63, 477–485, 2017.10.1373/clinchem.2016.258319
]Search in Google Scholar
[
Cohen MP, Hud E. Measurement of plasma glycoalbumin levels with a monoclonal antibody based ELISA. J Immunol Methods 122, 279–283, 1989.10.1016/0022-1759(89)90275-5
]Search in Google Scholar
[
Divani M, Georgianos PI, Didangelos T, Iliadis F, Makedou A, Hatzitolios A, Liakopoulos V, Grekas DM. Comparison of glycemic markers in chronic hemodialysis using continuous glucose monitoring. Am J Nephrol 47, 21–29, 2018.10.1159/00048584329275415
]Search in Google Scholar
[
Dozio E, Corradi V, Proglio M, Vianello E, Menicanti L, Rigolini R, Caprara C, de Cal M, Corsi Romanelli MM, Ronco C. Usefulness of glycated albumin as a biomarker for glucose control and prognostic factor in chronic kidney disease patients on dialysis (CKD-G5D). Diabetes Res Clin Pract 140, 9–17, 2018.10.1016/j.diabres.2018.03.01729596954
]Search in Google Scholar
[
Freedman BI. A critical evaluation of glycated protein parameters in advanced nephropathy: a matter of life or death: time to dispense with the hemoglobin A1C in end-stage kidney disease. Diabetes Care 35, 1621–1624, 2012.10.2337/dc12-0027337961422723586
]Search in Google Scholar
[
Fukami K, Shibata R, Nakayama H, Yamada K, Okuda S, Koga M. Serum albumin-adjusted glycated albumin reflects glycaemic excursion in diabetic patients with severe chronic kidney disease not treated with dialysis. J Diabetes Complications 29, 913–917, 2015.10.1016/j.jdiacomp.2015.06.00326164356
]Search in Google Scholar
[
Furusyo N, Koga T, Ai M, Otokozawa S, Kohzuma T, Ikezaki H, Schaefer EJ, Hayashi J. Utility of glycated albumin for the diagnosis of diabetes mellitus in a Japanese population study: results from the Kyushu and Okinawa Population Study (KOPS). Diabetologia 54, 3028–3036, 2011.10.1007/s00125-011-2310-621947435
]Search in Google Scholar
[
Hayashi A, Takano K, Masaki T, Yoshino S, Ogawa A, Shichiri M. Distinct biomarker roles for HbA1c and glycated albumin in patients with type 2 diabetes on hemodialysis. J Diabetes Complications 30, 1494–1499, 2016.10.1016/j.jdiacomp.2016.08.01527614726
]Search in Google Scholar
[
Inoue K, Goto A, Kishimoto M, Tsujimoto T, Yamamoto-Honda R, Noto H, Kajio H, Terauchi Y, Noda M. Possible discrepancy of HbA1c values and its assessment among patients with chronic renal failure, hemodialysis and other diseases. Clin Exp Nephrol 19, 1179–1183, 2015.10.1007/s10157-015-1110-6467978025824109
]Search in Google Scholar
[
Kobayashi H, Abe M, Yoshida Y, Suzuki H, Maruyama N, Okada K. Glycated albumin versus glycated hemoglobin as a glycemic indicator in diabetic patients on peritoneal dialysis. Int J Mol Sci 17, 619, 2016.10.3390/ijms17050619488144527120597
]Search in Google Scholar
[
Koga M, Inada S, Nakao T, Kawamori R, Kasayama S. The glycated albumin (GA) to HbA1c ratio reflects shorter-term glycemic control than GA: Analysis of patients with fulminant type 1 diabetes. J Clin Lab Anal 31, e22023, 2017.10.1002/jcla.22023681687127386821
]Search in Google Scholar
[
Meyer L, Chantrel F, Imhoff O, Sissoko A, Serb L, Dorey F, Fleury D, Smagala A, Kepenekian L, Krummel T, Le Floch JP, Kessler L. Glycated albumin and continuous glucose monitoring to replace glycated haemoglobin in patients with diabetes treated with haemodialysis. Diabet Med 30, 1388–1389, 2013.10.1111/dme.1229423909880
]Search in Google Scholar
[
National Kidney Foundation. KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 Update. Am J Kidney Dis 60, 850–886, 2012.10.1053/j.ajkd.2012.07.00523067652
]Search in Google Scholar
[
Peng F, Xia X, He F, Li Z, Huang F, Yu X. The effect of glycated hemoglobin and albumin-corrected glycated serum protein on mortality in diabetic patients receiving continuous peritoneal dialysis. Perit Dial Int 35, 566–575, 2015.10.3747/pdi.2014.00011459799025395497
]Search in Google Scholar
[
Rhee JJ, Ding VY, Rehkopf DH, Arce CM, Winkelmayer WC. Correlates of poor glycemic control among patients with diabetes initiating hemodialysis for end-stage renal disease. BMC Nephrol 16, 204, 2015.10.1186/s12882-015-0204-4467375326645204
]Search in Google Scholar
[
Sany D, Elshahawy Y, Anwar W. Glycated albumin versus glycated hemoglobin as glycemic indicator in hemodialysis patients with diabetes mellitus: Variables that influence. Saudi J Kidney Dis Transpl 24, 260–273, 2013.10.4103/1319-2442.109568
]Search in Google Scholar
[
Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modeling. Diabetes Care 27, 1487–1495, 2004.10.2337/diacare.27.6.148715161807
]Search in Google Scholar
[
Weykamp C, John WG, Mosca A, Hoshino T, Little R, Jeppsson JO, Goodall I, Miedema K, Myers G, Reinauer H, Sacks DB, Slingerland R, Siebelder C. The IFCC reference measurement system for HbA1c: a 6-year progress report. Clin Chem 54, 240–248, 2008.10.1373/clinchem.2007.09740218223132
]Search in Google Scholar
[
Yajima T, Yajima K, Hayashi M, Takahashi H, Yasuda K. Serum albumin-adjusted glycated albumin as a better indicator of glycemic control in Type 2 diabetes mellitus patients with short duration of hemodialysis. Diabetes Res Clin Pract 130, 148–153, 2017.10.1016/j.diabres.2017.05.02028641154
]Search in Google Scholar
